Karyopharm grants annual equity awards to CEO Paulson and CFO Mason under 2022 Plan

Karyopharm Therapeutics Inc.

CEO Richard Paulson receives 252,000 time-based RSUs and 252,000 target PSUs (0-200% vesting).
CFO Michael Mason receives 95,000 time-based RSUs and 80,000 target PSUs.
PSU vesting tied 33% each to: 3-year revenue, 3 clinical milestones, and relative TSR vs Nasdaq Biotech Index.
Clinical milestone PSUs have a 1-year minimum vesting; performance measured over 3-year periods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.